Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05349422 · ClinicalTrials.gov registry record · NA
Addressing Antihypertensive Medication Adherence Through EHR-enabled Teamlets in Primary Care
A NA study of Blood Pressure and Medication Adherence, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 1,726
- Enrollment target
- 1
- Study location
NCT05349422: Completed NA study of Blood Pressure and Medication Adherence, sponsored by NYU Langone Health.
NCT05349422 is a NA study of Blood Pressure and Medication Adherence that has completed, run by NYU Langone Health. The registered enrollment target is 1,726 participants, above the 270-participant average among 101 other Blood Pressure trials with a reported enrollment target (539% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05349422, a NA study of Blood Pressure and Medication Adherence, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,726 participants
- Enrollment target
- 1
- Study location
Study Summary
The study team will conduct a cluster randomized control trial in 10 NYU primary care practices to assess the effectiveness and implementation of the multicomponent intervention on medication adherence and blood pressure control for patients who are non-adherent to antihypertensive medications.
Primary Outcome
The percentage of days covered (PDC) is used to estimate medication adherence by looking at the percentage of days in which a person has access to the medication, over a given period of interest
Conditions Studied
Interventions
- BEHAVIORAL Electronic Health Record (EHR) Enabled Teamlets
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,726 participants |
| Start Date | 2022-10-06 |
| Est. Completion | 2025-05-11 |
| Phase | NA |
What the finished NCT05349422 record still lists
NCT05349422 is an interventional study that assigns participants to a tested intervention. Its 1,726 participants enrollment target places it among the larger protocols in the corpus, above the 270-participant average among 101 other Blood Pressure trials with a reported enrollment target (539% higher).
The record links to 2 conditions, with Blood Pressure appearing as the primary indexed condition, and to 1 intervention - of which Electronic Health Record (EHR) Enabled Teamlets is the first listed.
NCT05349422 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05349422 about?
NCT05349422 is a clinical study titled "Addressing Antihypertensive Medication Adherence Through EHR-enabled Teamlets in Primary Care". The study team will conduct a cluster randomized control trial in 10 NYU primary care practices to assess the effectiveness and implementation of the multicomponent intervention on medication adherence and blood pressure control for patients who are non-adherent to antihypertensive medications.
What is the current status of trial NCT05349422?
This trial is currently completed. It is a NA study. The enrollment target is 1,726 participants. The study started on 2022-10-06. Estimated completion is 2025-05-11.
What conditions does trial NCT05349422 study?
This clinical trial studies the following conditions: Blood Pressure, Medication Adherence.
What interventions are being tested in trial NCT05349422?
The interventions under investigation include: Electronic Health Record (EHR) Enabled Teamlets (BEHAVIORAL).
Who is sponsoring clinical trial NCT05349422?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05349422 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blood Pressure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05349422's enrollment target sits among peer trials
1,726 4th of 101 higher than 98 of 101 other Blood Pressure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Blood Pressure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Cocooned Moms Study
RECRUITING · NA
-
The GUARDIAN Trial
RECRUITING · NA
-
The Venous Distension Reflex and Orthostatic Hypertension
RECRUITING · NA
-
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
RECRUITING · NA
-
The Effect of Transcutaneous Stimulation on Blood Pressure in Spinal Cord Injury (SCI)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06898034 · 1,725 participants
Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
- NCT06413420 · 1,731 participants
SUNOSI® (Solriamfetol) Pregnancy Registry
- NCT04291612 · 1,715 participants
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
- NCT04712656 · 1,739 participants
Effects of CPAP Therapy on Blood Pressure and Heart Rate Variability in Obstructive Sleep Apnea
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI